Ramiprilate inhibits functional matrix metalloproteinase activity in Crohn's disease fistulas

Basic and Clinical Pharmacology and Toxicology

Volumn 109, Issue 3, 2011, Pages 208-216

  Efsen, Eva ^a   Særmark, Torben ^b   Hansen, Alastair ^a   Bruun, Eywin ^a   Brynskov, Jørn ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; EDETIC ACID; GELATINASE A; GELATINASE B; ILOMASTAT; MATRIX METALLOPROTEINASE; RAMIPRILAT; STROMELYSIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFECT; ENDOSCOPIC BIOPSY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SUBSTRATE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INTESTINE FISTULA; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN HYDROLYSIS;

ADULT; CROHN DISEASE; FEMALE; HUMANS; INTESTINAL FISTULA; MALE; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; RAMIPRIL; SUBSTRATE SPECIFICITY; TISSUE CULTURE TECHNIQUES;

FISTULA;

EID: 80051587956     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00713.x     Document Type: Article

References (45)

1. Falconi M, Pederzoli P. The relevance of gastrointestinal fistulae in clinical practice: a review. Gut 2001;49(Suppl. 4):iv2-10.
2. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
3. Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D'Haens G, Rutgeerts PJ et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009;58:940-8.
4. Pender SL, Fell JM, Chamow SM, Ashkenazi A, MacDonald TT. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 1998;160:4098-103.
5. Pender SL, Tickle SP, Docherty AJ, Howie D, Wathen NC, MacDonald TT. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997;158:1582-90.
6. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodelling. Trends Genet 1990;6:121-5.
7. Bode W, Maskos K. Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Biol Chem 2003;384:863-72.
8. Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999;117:814-22.
9. Louis E, Ribbens C, Godon A, Franchimont D, De Groote D, Hardy N et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000;120: 241-6.
10. Di Sabatino A, Saarialho-Kere U, Buckley MG, Gordon JN, Brancheri P, Rovedatti L et al. Stromelysin-1 and macrophage metalloelastase expression in the intestinal mucosa of Crohn's disease patients treated with infliximab. Eur J Gastroenterol Hepatol 2009;21:1049-55.
11. Wang YD, Yan PY. Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in ulcerative colitis. World J Gastroenterol 2006;12:6050-3.
12. Bister VO, Salmela MT, Karjalainen-Lindsberg ML, Uria J, Lohi J, Puolakkainen P et al. Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer. Dig Dis Sci 2004;49: 653-61.
13. Pedersen G, Saermark T, Kirkegaard T, Brynskov J. Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium. Clin Exp Immunol 2009;155:257-65.
14. Garg P, Vijay-Kumar M, Wang L, Gevirtz AT, Merlin D, Sitaraman SV. Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. Am J Physiol Gastrointest Liver Physiol 2009;296:G175-84.
15. Garg P, Rojas M, Ravi A, Bockbrader K, Epstein S, Vijay-Kumar M et al. Selective ablation of matrix metalloproteinase-2 exacerbates experimental colitis: contrasting role of gelatinases in the pathogenesis of colitis. J Immunol 2006;177:4103-12.
16. Oliver SJ, Firestein GS, Arsenault L, Cruz TF, Cheng TP, Banquerigo ML et al. Vanadate, an inhibitor of stromelysin and collagenase expression, suppresses collagen-induced arthritis. J Rheumatol 2007;34:1802-9.
17. Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH. Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression. J Rheumatol 2000;27:2761-8.
18. Tuomainen AM, Nyyssonen K, Laukkanen JA, Tervahartiala T, Tuomainen TP, Salonen JT et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 2007; 27:2722-8.
19. Endo T, Nakabayashi K, Sekiuchi M, Kuroda T, Soejima A, Yamada A. Matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in the peripheral blood of patients with various glomerular diseases and their implication in pathogenetic lesions: study based on an enzyme-linked assay and immunohistochemical staining. Clin Exp Nephrol 2006;10:253-61.
20. Kirkegaard T, Hansen A, Bruun E, Brynskov J. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 2004;53:701-9.
21. Grimaud JC, Munoz-Bongrand N, Siproudhis L, Abramowitz L, Sénéjoux A, Vitton V et al. Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease. Gastroenterology 2010;138:2275-81, 2281.e1.
22. Nielsen OH, Rogler G, Hahnloser D, Thomsen OØ. Diagnosis and management of fistulizing Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 2009;6:92-106.
23. Bataille F, Klebl F, Rummele P, Schroeder J, Farkas S, Wild PJ et al. Morphological characterisation of Crohn's disease fistulae. Gut 2004;53:1314-21.
24. Knight CG, Willenbrock F, Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett 1992;296:263-6.
25. Koon HW, Zhao D, Na X, Moyer MP, Pothoulakis C. Metalloproteinases and transforming growth factor-alpha mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes. J Biol Chem 2004;279:45519-27.
26. Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 1999;81:761-6.
27. Bowyer J, Heapy CG, Flannelly JK, Waterton JC, Maciewicz RA. Evaluation of a magnetic resonance biomarker of osteoarthritis disease progression: doxycycline slows tibial cartilage loss in the Dunkin Hartley guinea pig. Int J Exp Pathol 2009;90:174-81.
28. Li X, Meng Y, Yang XS, Mi LF, Cai SX. ACEI attenuates the progression of CCl4-induced rat hepatic fibrogenesis by inhibiting TGF-beta1, PDGF-BB, NF-kappaB and MMP-2, 9. World J Gastroenterol 2005;11:4807-11.
29. Nakagawa T, Kubota T, Kabuto M, Kodera T. Captopril inhibits glioma cell invasion in vitro: involvement of matrix metalloproteinases. Anticancer Res 1995;15:1985-9.
30. Ahimastos AA, Natoli AK, Lawler A, Blombery PA, Kingwell BA. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005;45:1194-9.
31. Pautke C, Bauer F, Tischer T, Kreutzer K, Weitz J, Kesting M et al. Fluorescence-guided bone resection in bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67:471-6.
32. Warner GT, Perry CM. Ramipril: a review of its use in the prevention of cardiovascular outcomes. Drugs 2002;62:1381-405.
33. Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T. Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol 2004;43:142-52.
34. Jonat C, Chung FZ, Baragi VM. Transcriptional downregulation of stromelysin by tetracycline. J Cell Biochem 1996;60:341-7.
35. Tanaka H, Takai S, Jin D, Furubayashi K, Inoue N, Kajimoto Y et al. Inhibition of matrix metalloproteinase-9 activity by trandolapril after middle cerebral artery occlusion in rats. Hypertens Res 2007;30:469-75.
36. Small W Jr, Molteni A, Kim YT, Taylor JM, Chen Z, Ward WF. Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. Breast Cancer Res Treat 1997;44:217-24.
37. Reddy MK, Baskaran K, Molteni A. Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med 1995;210:221-6.
38. Chen L, Re RN, Prakash O, Mondal D. Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med 1991;196:280-3.
39. Chung AW, Yang HH, Radomski MW, van Breemen C. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in Marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res 2008;102:e73-e85.
40. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008;198:320-31.
41. Lee CZ, Xu B, Hashimoto T, McCulloch CE, Yang GY, Young WL. Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke 2004;35:1715-9.
42. Choi DH, Moon IS, Choi BK, Paik JW, Kim YS, Choi SH et al. Effects of sub-antimicrobial dose doxycycline therapy on crevicular fluid MMP-8, and gingival tissue MMP-9, TIMP-1 and IL-6 levels in chronic periodontitis. J Periodontal Res 2004;39:20-6.
43. Baxter BT, Pearce WH, Waltke EA, Tillooy FN, Hallett JW Jr, Kent KC et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg 2002;36:1-12.
44. Ding R, McGuinness CL, Burnand KG, Sullivan E, Smith A. Matrix metalloproteinases in the aneurysm wall of patients treated with low-dose doxycycline. Vascular 2005;13:290-7.
45. Kaufmann TJ, Marx WF, Kallmes DF. A failure of matrix metalloproteinase inhibition in the prevention of rat intracranial aneurysm formation. Neuroradiology 2006;48:190-5.